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INTRODUCTION 
The best overall index of renal function is the glomerular filtration rate (GFR) [1]. Since measuring the GFR can 
be cumbersome and costly, estimation of GFR is essential for the diagnosis and evaluation of chronic kidney 
disease (CKD), defined as kidney damage or GFR <60 niL/min/1.73 m
2
 for ≥3 months and staged by levels of 
GFR according to the NKF KDOQI (The National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative) guidelines published in 2002 [2]. These now decade-old guidelines are under consideration for 
revision by the KDIGO (Kidney Disease: Improving Global Outcomes) CKD Work Group [3]. Several authors 
have proposed in the past different equations to estimate GFR based on serum creatinine concentration, the latter 
being determined by the individual's muscular mass in steady state, and thus by age, gender and ethnicity [4-8]. 
Among these equations, the one proposed by Cockcroft and Gault in 1976 [4] was doubtless the most popular for 
many years because of its simplicity and ease to calculate at the patient's bedside. However, this equation is an 
estimation of the creatinine clearance, not of the GFR, and was particularly imprecise, notably in CKD patients. 
In 1999, an equation derived from measured GFR (mGFR) was developed in the Modification of Diet in Renal 
Disease (MDRD) Study. This equation included the serum creatinine concentration and six other variables, 
subsequently abbreviated to four variables [5, 6]. This equation has been endorsed by the KDOQI guidelines and 
is currently used by most clinical laboratories [2]. Several limitations of the MDRD study equation were 
elaborated on in the literature [9-12], the major one being the systematic underestimation of mGFR >60 
mL/min/1.73 m
2
, which essentially translates in to overestimation of the CKD prevalence. A new equation, the 
CKD-Epidemiology Collaboration (CKD-EPI) equation, was proposed in 2009 for better estimation of GFR 
levels >60 mL/min/1.73 m
2
 [7]. 
ASSESSING THE PERFORMANCE OF EQUATIONS (OR WHY WE NEED PRECISION) 
Four main statistical tools are used when performance of equations must be evaluated: bias, precision, accuracy 
and CKD classification. 
Bias is defined as the mean (or median) difference between the estimated GFR (eGFR) and mGFR [13, 14]. It is 
a conceptualization of the systematic error. Because this error is systematic, it is relatively easy to assess. For 
example, if a particular equation systematically underestimates the mGFR by 5 or 10 mL/min/1.73 m
2
, it is not 
difficult for the clinicians to interpret the eGFR result for a given patient. Conversely, when considering the 
eGFR results in population studies, such a systematic error will be misleading in terms of CKD prevalence or 
CKD-related mortality and morbidity-associated risk [15, 16]. This was specifically observed with the MDRD 
equation, which by underestimating the mean mGFR, overestimates the CKD stage 3 prevalence in the general 
population [7, 15-18]. 
Precision is a concept that is frequently forgotten by most authors but it is, however, fundamental. Precision is 
usually expressed as standard deviation (SD) or interquartile range (IQR) of the bias, and thus represents the 
spread of 68% (assuming normal distribution) or 50% of the values around the bias, respectively. It 
conceptualizes the random error, which is much more difficult to assess and correct than the bias. The 
conceptualization is easier for the clinician to understand when precision is expressed as SD instead of IQR, 
because the former permits the estimation of the 95% range of eGFR values. Contrary to the bias, this type of 
error will have a low impact on the results in a population, e.g. the CKD prevalence. However, such an error 
could be misleading for the clinicians when interpreting an individual's eGFR result. In a patient with an mGFR 
of 60 mL/min/1.73 m
2
, an equation with a perfect bias (0 mL/min/1.73 m
2
) but a global precision (SD) of 10 
mL/min/1.73 m
2,
 would provide 95% probability so that the eGFR value is between 40 and 80 mL/min/1.73 m
2
, 
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something the clinicians would not be aware of when an eGFR value is routinely reported by a clinical 
laboratory. 
Accuracy combines bias and precision and it is easy to understand when presented as the percentage of eGFRs 
within a defined range of their respective mGFRs. Root mean square error also combines bias and precision but 
its conceptualization is more difficult to interpret in practice by clinicians. In the KDOQI guidelines, a range of ± 
30% with 90% of eGFRs in this range, was cited as a useful measure of accuracy [2]. As practicing clinicians, 
we have to question if such a goal is really sufficient for important clinical decisions, as, for example, whether a 
potential candidate could be a living kidney donor. In such situations, an accuracy of ± 15% could be more 
useful [9, 14]. 
CKD classification is one of the most important statistical tools for the clinicians when evaluating the 
performance of an equation on an individual level [9, 19]. It is related to the percentage of patients correctly 
classified by eGFR into the different CKD stages in comparison with the confirmatory test of mGFR [20]. 
Unfortunately, this statistical tool is not always used appropriately [9]. For example, some authors [7, 21] 
consider the eGFR as a reference, while many others correctly used the mGFR as a reference for defining the 
five CKD stages when assessing an equation's performance [19, 22-32]. An equation with high correct CKD 
classification would decrease the need for determining the mGFR and provide great confidence to the clinicians 
to implement an appropriate plan of action according to the individual's eGFR result. 
THE CKD-EPI EQUATION: WHAT IS (REALLY) NEW? 
The relationship between GFR and serum creatinine is different in healthy subjects and CKD patients [33, 34]. 
This physiological fact explains why the MDRD equation, developed exclusively from a CKD population, 
underestimates the high GFR levels. Because the authors of the CKD-EPI equation included a significant 
proportion of subjects with a 'normal' GFR, the serum creatinine variable was modelled as a spline with sex-
specific knots (0.7 and 0.9 mg/dL for women and men, respectively) and different exponents were applied to 
serum creatinine according to its level [7]. As expected, the performance of the new equation was globally better 
than the MDRD one. For example, in the external validation data set, the median bias (eGFR-mGFR), precision 
(IQR) and accuracy ±30% for the MDRD and CKD-EPI equations were: -5.5 versus -2.5 mL/min/1.73 m
2
, 18.3 
versus 16.6 mL/min/1.73 m
2
 and 81 versus 84%, respectively. However, it must be underlined that the improved 
performance of the CKD-EPI equation was essentially due to a lower bias [3 mL/min/1.73 m
2
 (55%) reduction], 
while precision remained comparable [1.7 mL/min.1.73 m
2
 (9%) reduction] and suboptimal. Accuracy ±30% 
was essentially unchanged [3.5% (4%) increase]. As expected too, for GFR >60 mL/min/1.73 m
2
 the CKD-EPI 
equation's bias was better [7 mL/min/1.73 m
2
 (67%) reduction], but meanwhile its precision declined by 12.9 
mL/ min/1.73m
2
 (114%), 11.3 versus 24.2 mL/min/1.73 m
2
 for mGFR <60 and >60 mL/min/1.73 m
2
, 




How can we explain this absence of a better precision in the new equation? Two main explanations could be 
advanced. First, the precision of an estimator will strongly depend on the precision of measuring serum 
creatinine (as a main biological variable) and GFR. In the vast majority of studies used as development data set 
for the CKD-EPI equation, serum creatinine has been measured by the Jaffe methods which are largely less 
precise, even if isotope dilution mass spectrometry traceable, than the enzymatic methods. This imprecision 
impacts the global accuracy of the new equation [35-37]. Hence, it is not surprising that the best accuracy of 
creatinine-based equations is seen in studies with serum creatinine measured by enzymatic assay in paediatric 
[38] or adult [14, 39] studies. In the development data set, only urinary clearances of subcu-taneously injected 
iothalamate were performed to measure GFR. In this measurement, precision is not the best [40] and, 
incidentally, the plasma clearance of iohexol has been shown to have a better precision and reproducibility [41-
43]. Secondly, the relative lack of precision of the CKD-EPI equation is probably due to the studied population 
[7]. Certainly, the population sample is impressive as the new equation has been built from a development data 
set including 5504 subjects (with an internal validation data set of 2750 subjects) and subsequently tested in an 
external validation data set of 3896 subjects. Although the MDRD cohort represented a relatively homogeneous 
population (CKD patients without diabetes), the CKD-EPI one included a more heterogeneous population with 
potentially different GFR-serum creatinine relationships [33, 34]. 
After its introduction, the CKD-EPI equation was studied in various populations. A PubMed database (last 
accessed 18 June 2012) search for GFR, MDRD and CKD-EPI in adults with a minimum of 50 mGFRs 
(estimates from smaller studies can be unreliable) and provided data for ± 30% accuracy recovered 26 
publications [7, 21, 26, 32, 39, 44-64]. The results for accuracy, bias and precision and their respective calculated 
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weighted average values are presented in Table 1. The CKD-EPI equation had a slightly better weighted average 
for ±30% accuracy of 1.8%, mean/median bias of 3.5/0.1 mL/min/1.73 m
2
, respectively, and precision of 1.1 
mL/min/1.73 m
2
 compared with the MDRD one. These differences are not clinically significant with the 
exception of a better mean bias of 3.5 mL/ min/1.73 m
2
 when considering the very low GFR levels. The 
differences between the two equations by weighted average analysis for strata of GFR >60 mL/min/1.73 m
2
 were 
again clinically insignificant. 
CONCLUSION: POPULATION VERSUS PATIENT IMPLICATIONS 
At best, the CKD-EPI equation might be considered as an evolution but not a revolution. By improving the 
systematic error of the CKD-EPI equation in comparison with the MDRD one, the advantage of the new 
equation is when we think in terms of population [7, 14, 17, 65]. In this view, it seems that the CKD-EPI 
equation performs better to define the CKD stage 3 prevalence in a general population, and especially in the 
younger subjects [66]. However, without the confirmatory mGFR test, this conclusion is not reliable and there 
are still reasons to think that the new equation overestimates the CKD prevalence in the Caucasian population 
[17]. In the same thought, it has been recently proved in different cohorts that the better bias linked to the CKD-
EPI equation leads to a better prediction of the CKD-associated risk of mortality [65, 67, 68]. Although 
impressive, we have already underlined the limitations of this type of epidemiological studies [69]. 
The superiority of the CKD-EPI equation could be accepted in epidemiological trials but this is certainly more 
questionable if we are thinking in terms of 'the patient'. If we have to know and follow the GFR of a given 
individual, the concept of precision becomes very important and in this context, the CKD-EPI equation is clearly 
lacking any additional value. This assertion is reinforced if we consider the percentage of subjects who are 
correctly classified into the five CKD stages. In the validation data set, Levey et al. [7] demonstrated a 
concordance between the measured and estimated CKD stages of 69%, while Murata et al. [21] observed a 
correct classification of >70% only in 6 of the 25 GFR studied groups. Bjork et al. [32] found an overall proper 
CKD classification of 69%. All these results should be considered suboptimal as in the case of the 38% overall 
CKD misclassifications reported for the MDRD equation in a recent review [9]. 
Obviously, both the CKD-EPI and MDRD equations are not 'magic'. Serum creatinine remains the principal 
variable of the GFR-estimating equations, and if it is not accurately representing the individual's muscular mass 
[70], there is little chance that including the creatinine into the equations would improve their performance. 
Classical examples are hyperfil-trating diabetic patients [49, 59, 71] and cirrhotic [72, 73], renal transplanted [21, 
51, 55], elderly [21, 73] and anorectic patients [73]. 
As clinicians, we have to know the GFR of individuals, not of populations. We have to treat patients, not 
statistical risks by associations. Therefore, we have to minimize the random error of the estimator, not only the 
systematic one. In fact, the true question might not be 'Is the CKD-EPI equation better for the estimation of my 
given patient?' but maybe 'Is there any chance that any creatinine-based equation is precise enough in my 
patient?' and 'Would it not be better to measure GFR by a reference method in my specific patient?' [20]. 
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mGFR ± SD 
(range) 
Accuracy Bias Precision 
30% 15% Mean Median SD of mean bias 
MDRD CKD-EPI MDRD CKD-EPI MDRD CKD-EPI MDRD CKD-EPI MDRD CKD-EPI 
Murata et al.[21] Iothalamate Yes IDMS Mixed 5238 56 ± 30 77.6 78.4   -4.1 -0.7     




Yes IDMS Mixed 3896 68 ± 36 80.6 84.1     5.5 2.5   
Eriksen et al. [39] Iohexol 
plasma 
Yes IDMS General (no CKD) 1621 92 ± 14 93 95     1.3 2.9   
Bjork et al. [32] Iohexol 
plasma 
Yes IDMS Mixed 1397 44 (12-116) 79.5 79.1   -2.0 2.0 -0.8 0.8   
Buron et al. [58] Inulin Yes LCMS KT recipients 1249 54 ± 18 (15-90) 85 81   -0.5 3.9   12.2 12.6 
Nyman et al. [47] Iohexol 
plasma 
Yes IDMS Mixed 850 55 (9-121) 79.9 79.5   1.0 4.0 1.2 2.3   
Iliadis et al. [57] 51Cr-EDTA 
plasma 
Yes IDMS DM Type 2 448 73 ± 23 78.8 80.7   7.5 7.1   13.4 12.0 
Lane et al. [60] 125I-
iothalamate 
Yes ClClin Pre- and post-
nephrectomy 
425 50 (median)  
(4-142) 
75 80     -1.0 -1.7   
Cirillo et al. [56] Inulin Yes IDMS Mixed 356 72 ± 36 87.4 88.2   -5.2 -0.9   14.9 13.2 




Yes IDMS Mixed 271 73 ± 30 81.2 84.5   0.8 4.5   24.7 16.7 
Tent et al. [50] 125I-
iothalamate 
Yes ClClin Pre-nephrectomy 253 103 ± 15 73 89   -22.0 -14.0 -22.0 -14.0   
Post-nephrectomy 253 66 ± 11 71 89   -15.0 -10.0 -15.0 -11.0   
Teo et al. [54] 99mTc-DTPA 
plasma 
Yes IDMS CKD 232 52 ± 28 79.7 82.8 50 50 -1.0 1.1 -3.0 -1.2   
White et al. [46] 99mTc-DTPA 
plasma 





Yes IDMS Oncology 185 85 ± 20 88.6 89.7   0.8 1.2   16.5 13.4 




Yes IDMS KT recipients 170 40 (12-83) 71.8 64.1   4.5 8.1 4.1 7.4 10.0 10.9 
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Jones et al. [63] 99mTc-DTPA 
plasma 
Yes IDMS Evaluation of GFR 169 71 (5-150) 81 86         
Kukla et al. [51] 125I-
iothalamate 







KT recipients 1 
year post-KT 
81 57 ± 18 75.0 66.7   2.4 6.9   15.7 15.9 
Silveiro et al. [59] 51Cr-EDTA 
plasma 
Yes IDMS DM Type 2 105 103 ± 23 64 67   -25.0 -20.0   22.0 21.0 
Orskov et al. [52]a 51Cr-EDTA 
plasma 
Yes IDMS Polycystic 
kidney 
disease 





Yes IDMS CKD 100 51 ± 28 62.7 68.0 27.3 30.7 -9.2 -7.9     
Soares et al. [53] 51Cr-EDTA 
plasma 
Yes IDMS Healthy 96 112 ± 24 69 85 40 55 -18.0 -10.0   26.0 24.0 
Bargnoux et al. 
[64] 
99mTc-DTPA Yes IDMS KT recipients 85 53 ± 21 72.9 72.9   -4.3 -0.2   14.1 14.7 
Tent et al. [61] 125I- 
iothalamate 







CKD 65 58 ± 29 77 82   -11.0 -7.0 -8.0 -6.0   




Yes IDMS Liver transplant 59 52 (48-57) 69.5 64.4   -4.3 -9.7     











Healthy 55 98 ± 20 80 90 47 60 -19.0 -9.0   20.0 18.0 




Yes IDMS CKD 50 N/A 74 72 52 46   -1.5 4.9   
Calculated average weighted values from available data in all studies 80.2 82.0 41.5 47.7 -3.5 0.0 1.1 1.0 14.9 13.8 
Calculated average weighted values from available data in all studies with analysis for strata of 
mGFR >60 mL/ min/1.73m2c 
87.1 89.4 46.0 52.4 -2.0 2.2 -1.7 -0.7 13.4 13.0 
MDRD, simplified (4 variables), re-expressed with calibrated serum creatinine, Modification of Diet in Renal Disease Study equation; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; GFR, glomerular filtration 
rate; SCr, serum creatinine calibrated to IDMS (isotope dilution mass spectroscopy), LCMS (liquid chromatography-mass spectrometry) or ClClin (Cleveland Clinic Laboratory); mGFR, measured GFR in mL/min/1.73 m2—urinary 
clearance unless otherwise described; Accuracy, % of GFR estimates within ±30% and ±15% of mGFRs; Bias, estimated minus measured GFR in mL/min/1.73 m2 (values for the mean bias in italic type were calculated if possible 
whenever not provided); Precision, one standard deviation (SD) of mean bias in mL/min/1.73 m2; 99mTc-DTPA, 99mtechnetium-diethylenetriamine pentaacetic acid; 51Cr-EDTA, 51chromium-ethylene diamine tetraacetic acid; CKD, chronic 
kidney disease; KT, kidney transplant; DM, diabetes mellitus. 
aStudy design included some SCr measurements not exactly on the day of GFR measurement. 
bData calculated for accuracy ±30%, accuracy ±15%, mean bias, median bias and precision from analysis of 18245, 690, 12303, 9484 and 3572 mGFRs, respectively.  
cData calculated for accuracy ±30%, accuracy ±15%, mean bias, median bias and precision from analysis of 1950, 132, 1072, 1048 and 1000 mGFRs, respectively. 
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OPPONENT'S COMMENTS 
We congratulate Dr Delanaye and colleagues on their scholarly review of GFR estimation and the comparative 
performance of the CKD-EPI versus MDRD Study equations. We agree with them about the importance of 
ascertainment of GFR in clinical decisions, the practicality of estimating the GFR from serum creatinine, the 
greater accuracy of the CKD-EPI versus MDRD study equation and the persisting imprecision of GFR estimates 
as an irremediable limitation of variation in non-GFR determinants of serum creatinine. We also agree that the 
CKD-EPI equation represents an evolution, not a revolution, in GFR estimation, but we disagree with their 
conclusion that we should not make the change to report the eGFR using the CKD-EPI equation. At present, 
there are hundreds of millions of creatinine measurements performed each year for the purpose of estimating the 
GFR. For the vast majority of these measurements, it is not possible to measure GFR. 
Our disagreement rests on three main arguments. First, their discussion on the limitations in measurement 
methods is not relevant when comparing the performance of two equations in the same dataset. Welldone 
studies, such as ours [1], show a consistent improvement in bias at a higher GFR and in overall accuracy [2]. 
Second, they erroneously characterize the performance of the two equations as comparable. While we agree that 
the improvement in precision is small, with the improvement in bias, the resulting improvement in accuracy is 
clinically important. For example, in our study, the percent of large errors ( >30% of the measured GFR) 
decreased from 19.4 to 15.9% (18%) across the range of GFRs, and from 17.7 to 13.2% (25%) for eGFR 60-89 
ml/min per 1.73 m
2
 [1]. These results represent a large and meaningful improvement in performance. Third, they 
dismiss the reduction in prevalence estimates and improvement in risk stratification as not relevant to clinical 
practice. However, these improvements translate directly to more accurate individual decision making for 
disease detection and prognosis, key elements in patient care. Moreover, these improvements are observed in 
large subgroups at low risk in whom there has been concerns over overdiagnosis of CKD (middle-aged people, 
women and whites). Reporting eGFR using the CKD-EPI equation would mean that substantially fewer patients 
would have to worry about an erroneous diagnosis of kidney disease and the risk for the future. 
At this time, the CKD-EPI equation maximizes the information available from the serum creatinine 
concentration. Evolution is a slow process. Gradual changes cannot be ignored. 
Lesley A. Inker and Andrew S. Levey 
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